Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Peter Nightingale, Chim Lang, Dana Dawson, Michael Frenneaux

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

ABSTRACT  Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

Original languageEnglish
Pages (from-to)693-698
Number of pages6
JournalFuture cardiology
Volume10
Issue number6
DOIs
Publication statusPublished - Nov 2014

Fingerprint

Perhexiline
Heart Failure
Placebos
Exercise

Cite this

Singh, S., Beadle, R., Cameron, D., Rudd, A., Bruce, M., Jagpal, B., ... Frenneaux, M. (2014). Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. Future cardiology, 10(6), 693-698. https://doi.org/10.2217/fca.14.62

Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. / Singh, Satnam; Beadle, Roger; Cameron, Donnie; Rudd, Amelia; Bruce, Maggie; Jagpal, Baljit; Schwarz, Konstantin; Brindley, Gemma; Mckiddie, Fergus; Nightingale, Peter; Lang, Chim; Dawson, Dana; Frenneaux, Michael.

In: Future cardiology, Vol. 10, No. 6, 11.2014, p. 693-698.

Research output: Contribution to journalArticle

Singh, S, Beadle, R, Cameron, D, Rudd, A, Bruce, M, Jagpal, B, Schwarz, K, Brindley, G, Mckiddie, F, Nightingale, P, Lang, C, Dawson, D & Frenneaux, M 2014, 'Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome' Future cardiology, vol. 10, no. 6, pp. 693-698. https://doi.org/10.2217/fca.14.62
Singh, Satnam ; Beadle, Roger ; Cameron, Donnie ; Rudd, Amelia ; Bruce, Maggie ; Jagpal, Baljit ; Schwarz, Konstantin ; Brindley, Gemma ; Mckiddie, Fergus ; Nightingale, Peter ; Lang, Chim ; Dawson, Dana ; Frenneaux, Michael. / Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. In: Future cardiology. 2014 ; Vol. 10, No. 6. pp. 693-698.
@article{f4bcc83b3fb24da59119836984f84208,
title = "Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome",
abstract = "ABSTRACT  Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.",
author = "Satnam Singh and Roger Beadle and Donnie Cameron and Amelia Rudd and Maggie Bruce and Baljit Jagpal and Konstantin Schwarz and Gemma Brindley and Fergus Mckiddie and Peter Nightingale and Chim Lang and Dana Dawson and Michael Frenneaux",
year = "2014",
month = "11",
doi = "10.2217/fca.14.62",
language = "English",
volume = "10",
pages = "693--698",
journal = "Future cardiology",
issn = "1744-8298",
number = "6",

}

TY - JOUR

T1 - Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

AU - Singh, Satnam

AU - Beadle, Roger

AU - Cameron, Donnie

AU - Rudd, Amelia

AU - Bruce, Maggie

AU - Jagpal, Baljit

AU - Schwarz, Konstantin

AU - Brindley, Gemma

AU - Mckiddie, Fergus

AU - Nightingale, Peter

AU - Lang, Chim

AU - Dawson, Dana

AU - Frenneaux, Michael

PY - 2014/11

Y1 - 2014/11

N2 - ABSTRACT  Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

AB - ABSTRACT  Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

U2 - 10.2217/fca.14.62

DO - 10.2217/fca.14.62

M3 - Article

VL - 10

SP - 693

EP - 698

JO - Future cardiology

JF - Future cardiology

SN - 1744-8298

IS - 6

ER -